Analysis of Hematological Examination Results in Pulmonary Tuberculosis (TB) Patients Undergoing Intensive Phase Anti-Tuberculosis Drug Therapy
Article Sidebar
Main Article Content
Asbar Tanjung
Abstract
The intensive phase of anti-tuberculosis (TB) drug therapy consists of a combination of
antibiotics, including Isoniazid (INH), Rifampicin (RIF), Pyrazinamide (PZA), and
Ethambutol (EMB). The primary goal of this therapy is to inhibit the growth and spread
of Mycobacterium tuberculosis, preventing its migration from the lungs to other organs.
However, intensive-phase therapy may result in both major and minor side effects. This
study aims to analyze the hematological profiles of pulmonary TB patients undergoing
intensive-phase anti-tuberculosis treatment. The respondents were pulmonary TB
patients recruited from primary healthcare centers within the East Bekasi District,
Bekasi City. Those who met the sample criteria underwent hematological examinations,
including hemoglobin (Hb), hematocrit (HCT), red blood cell count, white blood cell
count, and platelet count. The tests were conducted using the electrical impedance
method with a hematology analyzer. The hematological examination revealed a trend of
low hemoglobin levels, with the average Hb recorded at 11.98 ± 8.65 g/dL.
Additionally, abnormal blood parameters were observed, with 33.3% of patients
experiencing erythropenia, 57% showing thrombocytopenia, 33% presenting
leukopenia, and 20% exhibiting leukocytosis. These findings confirm that intensive-
phase anti-tuberculosis therapy affects the hematological profiles of pulmonary TB
patients, highlighting the need for close monitoring during treatment.
Downloads
Article Details
Copyright (c) 2024 Asbar Tanjung
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Anemia Is a Strong Predictor of Wasting, Disease Severity, and Progression, in Clinical Tuberculosis (TB), 14 Nutrients 1 (2022). https://doi.org/10.3390/nu14163318 DOI: https://doi.org/10.3390/nu14163318
Balepur, S. S., & Schlossberg, D. (2017). Hematologic complications of tuberculosis. Tuberculosis and Nontuberculous Mycobacterial Infections, 529–539. https://doi.org/10.1128/9781555819866.ch31 DOI: https://doi.org/10.1128/9781555819866.ch31
Burhan, E., Soeroto, A. Y., & Isbaniah, F. (2020). Pedoman Nasional Pelayanan Kedokteran-Tata Laksana Tuberkulosis-Kemeskes Ri. In Ebook Umum_Pnpk_Revisi_2020 (Vol. 6, Issue August).
Chaparro, C. M., & Suchdev, P. S. (2019). Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. Annals of the New York Academy of Sciences, 1450(1), 15–31. https://doi.org/10.1111/nyas.14092 DOI: https://doi.org/10.1111/nyas.14092
Dasaradhan, T., Koneti, J., Kalluru, R., Gadde, S., Cherukuri, S. priya, & Chikatimalla, R. (2022). Tuberculosis-Associated Anemia: A Narrative Review. Cureus, 14(8). https://doi.org/10.7759/cureus.27746 DOI: https://doi.org/10.7759/cureus.27746
Jamwal, M., Sharma, P., & Das, R. (2020). Laboratory Approach to Hemolytic Anemia. Indian Journal of Pediatrics, 87(1), 66–74. https://doi.org/10.1007/s12098-019-03119-8 DOI: https://doi.org/10.1007/s12098-019-03119-8
Kassa, E., Enawgaw, B., Gelaw, A., & Gelaw, B. (2016). Effect of anti-tuberculosis drugs on hematological profiles of tuberculosis patients attending at University of Gondar Hospital, Northwest Ethiopia. BMC Hematology, 16(1), 1–11. https://doi.org/10.1186/s12878-015-0037-1 DOI: https://doi.org/10.1186/s12878-015-0037-1
Kemenkes RI. (2018). Hasil Riset Kesehatan Dasar Tahun 2018. Kementrian Kesehatan RI, 53(9), 1689–1699.
Kemenkes RI. (2020). Strategi Nasional Penanggulangan Tuberkulosis di Indonesia 2020-2024. Pertemuan Konsolidasi Nasional Penyusunan STRANAS TB, 135.
Khan, M. K., Islam, M. N., Ferdous, J., & Alam, M. M. (2019). An Overview on Epidemiology of Tuberculosis. Mymensingh Medical Journal : MMJ, 28(1), 259–266.
Lasocki, S., Pène, F., Ait-Oufella, H., Aubron, C., Ausset, S., Buffet, P., Huet, O., Launey, Y., Legrand, M., Lescot, T., Mekontso Dessap, A., Piagnerelli, M., Quintard, H., Velly, L., Kimmoun, A., & Chanques, G. (2020). Management and prevention of anemia (acute bleeding excluded) in adult critical care patients. Annals of Intensive Care, 10(1). https://doi.org/10.1186/s13613-020-00711-6 DOI: https://doi.org/10.1186/s13613-020-00711-6
Pinho, S., & Frenette, P. S. (2019). Haematopoietic stem cell activity and interactions with the niche. Nature Reviews Molecular Cell Biology, 20(5), 303–320. https://doi.org/10.1038/s41580-019-0103-9 DOI: https://doi.org/10.1038/s41580-019-0103-9
Pratama, N. Y. I., Zulkarnain, B. S., Soedarsono, & Fatmawati, U. (2021). Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy. Journal of Basic and Clinical Physiology and Pharmacology, 32(4), 777–781. https://doi.org/doi:10.1515/jbcpp-2020-0468 DOI: https://doi.org/10.1515/jbcpp-2020-0468
Rodriguez-Takeuchi, S. Y., Renjifo, M. E., & Medina, F. J. (2019). Extrapulmonary tuberculosis: Pathophysiology and imaging findings. Radiographics, 39(7), 2023–2037. https://doi.org/10.1148/rg.2019190109 DOI: https://doi.org/10.1148/rg.2019190109
Sadewo, S. W., Salam, A., & Rialita, A. (2016). Gambaran Status Anemia pada Pasien Tuberkulosis Paru di Unit Pengobatan Penyakit Paru-Paru Provinsi Kalimantan Barat Tahun 2010-2012 Satrio. Jurnal Cerebellum, 2, 590–600.
Shah, A. R., Desai, K. N., & Maru, A. M. (2022). Evaluation of hematological parameters in pulmonary tuberculosis patients. Journal of Family Medicine and Primary Care, 11(8), 4424–4428. https://doi.org/10.4103/jfmpc.jfmpc_2451_21 DOI: https://doi.org/10.4103/jfmpc.jfmpc_2451_21
Sotgiu, G., Centis, R., D’ambrosio, L., & Migliori, G. B. (2015). Tuberculosis treatment and drug regimens. Cold Spring Harbor Perspectives in Medicine, 5(5), a017822. https://doi.org/10.1101/cshperspect.a017822 DOI: https://doi.org/10.1101/cshperspect.a017822
Wallis, R. S., Ginindza, S., Beattie, T., Arjun, N., Sebe, M., Likoti, M., Edward, V. A., Rassool, M., Ahmed, K., Fielding, K., Ahidjo, B. A., Vangu, M. D. T., & Churchyard, G. (2021). Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. The Lancet Respiratory Medicine, 9(8), 897–908. https://doi.org/10.1016/S2213-2600(20)30448-3 DOI: https://doi.org/10.1016/S2213-2600(20)30448-3
Zivot, A., Lipton, J. M., Narla, A., & Blanc, L. (2018). Erythropoiesis: Insights into pathophysiology and treatments in 2017. Molecular Medicine, 24(1), 1–15. https://doi.org/10.1186/s10020-018-0011-z DOI: https://doi.org/10.1186/s10020-018-0011-z
